

Freedom of Information Request	FOI 23-530	10 November 2023
--------------------------------	------------	------------------

Your request

You requested the following:

We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajoovy, Aimovig, Emgality, Vyepti, Vydura & Aquipta) for migraine. Could you please answer the following:

1. Does the trust commission/fund Botox treatment for migraine (Y/N)?
2. Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?
3. Does the trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust (Y/N)? In case the trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments?
4. In case the trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.
5. How many patients have been treated with the following drugs in the past 4 months:
 - Atogepant (Aquipta) – any disease
 - Erenumab (Aimovig) - any disease
 - Eptinezumab (Vyepti) – any disease
 - Fremanezumab (Ajoovy) - any disease
 - Galcanezumab (Emgality) - any disease
 - Rimegepant (Vydura) – any disease
 - Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

Our response

1. Yes.
2. Yes.
3. Yes.
4. N/A.
5. We are not able to provide information on the treatment drugs prescribed to individual patients as it is not recorded centrally. To comply with your request, we would need to review every patient record which we have established would take in excess of 18 hours to undertake and therefore exceeds the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. This is not an exemption which requires us to consider the application of the public interest test.